Islet and stem cell encapsulation for clinical transplantation

Review of Diabetic Studies

Volumn 11, Issue 1, 2014, Pages 84-101

  Krishnan, Rahul ^a   Alexander, Michael ^a   Robles, Lourdes ^a   Foster, Clarence E ^a,b   Lakey, Jonathan R T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Encapsulation; Insulin producing cell; Stem cell; Tissue engineering; Transplantation; Type 1 diabetes

Indexed keywords

ALGINIC ACID; BARIUM; BIOMATERIAL; HEMOGLOBIN A1C; INTERLEUKIN 1; INTERLEUKIN 6; MACROGOL; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

CELL ENCAPSULATION; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CELLULAR PARAMETERS; EXTRAVASCULAR DEVICE; FIBROSIS; GRAFT FUNCTION; GRAFT HYPOXIA; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; HYDROGEL; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVASCULAR DEVICE; MICROCAPSULE; MICROENCAPSULATION; NANOENCAPSULATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PANCREAS ISLET CELL; PLANAR DEVICE; PORE SIZE; PREVASCULARIZED DEVICE; REVIEW; STEM CELL; THERACYTE; TUBULAR DEVICE; VASCULARIZED DEVICE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; DIABETES MELLITUS, TYPE 1; HETEROTOPIC TRANSPLANTATION; IMMUNOLOGY; PANCREAS ISLET TRANSPLANTATION; PROCEDURES; STEM CELL TRANSPLANTATION; TRENDS; XENOGRAFT;

ANIMALS; BIOCOMPATIBLE MATERIALS; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 84906930648     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2014.11.84     Document Type: Review

References (183)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004. 27(Suppl 1):S5-S10.
2. Shenkman RM, Chalmers JJ, Hering BJ, Kirchhof N, Papas KK. Quadrupole magnetic sorting of porcine islets of Langerhans. Tissue Eng Part C Methods 2009. 15:147-156.
3. Langer RM. Islet transplantation: lessons learned since the Edmonton breakthrough. Transplant Proc 2010. 42:1421-1424.
4. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967. 61:827-837.
5. Lillehei RC, Ruix JO, Aquino C, Goetz F. Transplantation of the pancreas. Acta Endocrinol Suppl (Copenh) 1976. 205:303-320.
6. Chapo Bortagaray M, Zelasco JF, Bava A, Baun P, Cassin E, Crouzel G, Justo J, Lori R, Maquieira N, Mathov E, et al. Partial hemotransplant of the pancreas in the diabetic patient. Physiopathological basis for its location in the neck. 2 cases. Prensa Med Argent 1970. 57:220-224.
7. Sutherland DE. Pancreas and islet transplantation. II. Clinical trials. Diabetologia 1981. 20:435-450.
8. Teixeira E, Monteiro G, De Cenzo M, Teixeira A, Bergan JJ. Transplantation of the isolated pancreas: report on the first human case. Bull Soc Int Chir 1970. 29:337-344.
9. Connolly JE, Martin DC, Steinberg T, Gwinup G, Gazzaniga AB, Bartlett RH. Clinical experience with pancreaticoduodenal transplantation. Arch Surg 1973. 106:489-494.
10. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Henderson RG, Aziz S, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979. 2:1033-1036.
11. Segmental pancreatic transplantation. International workshop, Munich/Spitzingsee. Horm Metab Res Suppl, 1983, 1-104.
12. Squifflet JP, Malaise J, Van Ophem D, Marcelis V, Land WG, Euro SPKSG. The history of the EuroSPK -Study Group. Acta Chir Belg 2008. 108:67-69.
13. Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001. 233:463-501.
14. Sollinger HW, Stratta RJ, D'Alessandro AM, Kalayoglu M, Pirsch JD, Belzer FO. Experience with simultaneous pancreas-kidney transplantation. Ann Surg 1988. 208:475-483.
15. Sollinger HW, Cook K, Kamps D, Glass NR, Belzer FO. Clinical and experimental experience with pancreaticocystostomy for exocrine pancreatic drainage in pancreas transplantation. Transplant Proc 1984. 16:749-751.
16. Starzl TE, Iwatsuki S, Shaw BW Jr, Greene DA, Van Thiel DH, Nalesnik MA, Nusbacher J, Diliz-Pere H, Hakala TR. Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet 1984. 159:265-272.
17. Squifflet JP, Gruessner RW, Sutherland DE. The history of pancreas transplantation: past, present and future. Acta Chir Belg 2008. 108:367-378.
18. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000. 343:230-238.
19. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes 2005. 54:2060-2069.
20. Ault A. Edmonton's islet success tough to duplicate elsewhere. Lancet 2003. 361:2054.
21. Hardy MA, Witkowski P, Sondermeijer H, Harris P. The long road to pancreatic islet transplantation. World J Surg 2010. 34:625-627.
22. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012. 35:1436-1445.
23. Hafiz MM, Faradji RN, Froud T, Pileggi A, Baidal DA, Cure P, Ponte G, Poggioli R, Cornejo A, Messinger S, et al. Immunosuppression and procedurerelated complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 2005. 80:1718-1728.
24. Niclauss N, Bosco D, Morel P, Giovannoni L, Berney T, Parnaud G. Rapamycin impairs proliferation of transplanted islet beta cells. Transplantation 2011. 91:714-722.
25. Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, Winkel L, Remy P, Goddard M, Lefaucheur JP, Brugieres P, et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000. 11:1723-1729.
26. Eriksdotter-Jonhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O, Andreasen N, Blennow K, Bogdanovic N, Jelic V, Kadir A, et al. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012. 33:18-28.
27. Fernandez M, Barcia E, Fernandez-Carballido A, Garcia L, Slowing K, Negro S. Controlled release of rasagiline mesylate promotes neuroprotection in a rotenoneinduced advanced model of Parkinson's disease. Int J Pharm 2012. 438:266-278.
28. Huber A, Padrun V, Deglon N, Aebischer P, Mohler H, Boison D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci U S A 2001. 98:7611-7616.
29. Jeon Y. Cell based therapy for the management of chronic pain. Korean J Anesthesiol 2011. 60:3-7.
30. Hering BJ. Islet transplantation for patients with type 1 diabetes; results, research priorities, and reasons for optimism. Graft 1999. 2:12-27.
31. Shapiro AM, Nanji SA, Lakey JR. Clinical islet transplant: current and future directions towards tolerance. Immunol Rev 2003. 196:219-236.
32. Bisceglie V. Uber die antineoplastische Immunität; heterologe Einpflanzung von Tumoren in Hühnerembryonen. Ztschr f Krebsforsch 1933. 40:122-140.
33. O'Sullivan ES, Johnson AS, Omer A, Hollister-Lock J, Bonner-Weir S, Colton CK, Weir GC. Rat islet cell aggregates are superior to islets for transplantation in microcapsules. Diabetologia 2010. 53:937-945.
34. Kim AR, Hwang JH, Kim HM, Kim HN, Song JE, Yang YI, Yoon KH, Lee D, Khang G. Reduction of inflammatory reaction in the use of purified alginate microcapsules. J Biomater Sci Polym Ed 2013. 24:1084-1098.
35. Langlois G, Dusseault J, Bilodeau S, Tam SK, Magassouba D, Halle JP. Direct effect of alginate purification on the survival of islets immobilized in alginatebased microcapsules. Acta Biomater 2009. 5:3433-3440.
36. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980. 210:908-910.
37. Cui W, Barr G, Faucher KM, Sun XL, Safley SA, Weber CJ, Chaikof EL. A membrane-mimetic barrier for islet encapsulation. Transplant Proc 2004. 36:1206-1208.
38. Lamb M, Storrs R, Li S, Liang O, Laugenour K, Dorian R, Chapman D, Ichii H, Imagawa D, Foster C 3rd, et al. Function and viability of human islets encapsulated in alginate sheets: in vitro and in vivo culture. Transplant Proc 2011. 43:3265-3266.
39. Lum ZP, Tai IT, Krestow M, Norton J, Vacek I, Sun AM. Prolonged reversal of diabetic state in NOD mice by xenografts of microencapsulated rat islets. Diabetes 1991. 40:1511-1516.
40. Veriter S, Mergen J, Goebbels RM, Aouassar N, Gregoire C, Jordan B, Leveque P, Gallez B, Gianello P, Dufrane D. In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation. Tissue Eng Part A 2010. 16:1503-1513.
41. Yang H, O'Hali W, Kearns H, Wright JR Jr. Longterm function of fish islet xenografts in mice by alginate encapsulation. Transplantation 1997. 64:28-32.
42. Zhi ZL, Kerby A, King AJ, Jones PM, Pickup JC. Nano-scale encapsulation enhances allograft survival and function of islets transplanted in a mouse model of diabetes. Diabetologia 2012. 55:1081-1090.
43. Dufrane D, Goebbels RM, Gianello P. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation 2010. 90:1054-1062.
44. Dufrane D, Goebbels RM, Saliez A, Guiot Y, Gianello P. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation 2006. 81:1345-1353.
45. Elliott RB, Escobar L, Tan PL, Garkavenko O, Calafiore R, Basta P, Vasconcellos AV, Emerich DF, Thanos C, Bambra C. Intraperitoneal alginateencapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc 2005. 37:3505-3508.
46. Gianello P, Dufrane D. Correction of a diabetes mellitus type 1 on primate with encapsulated islet of pig pancreatic transplant. Bull Mem Acad R Med Belg 2007. 162:439-449.
47. Basta G, Montanucci P, Luca G, Boselli C, Noya G, Barbaro B, Qi M, Kinzer KP, Oberholzer J, Calafiore R. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care 2011. 34:2406-2409.
48. Calafiore R, Basta G, Luca G, Lemmi A, Montanucci MP, Calabrese G, Racanicchi L, Mancuso F, Brunetti P. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 2006. 29:137-138.
49. Calafiore R, Basta G, Luca G, Lemmi A, Racanicchi L, Mancuso F, Montanucci MP, Brunetti P. Standard technical procedures for microencapsulation of human islets for graft into nonimmunosuppressed patients with type 1 diabetes mellitus. Transplant Proc 2006. 38:1156-1157.
50. Tuch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V, Philips R. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care 2009. 32:1887-1889.
51. Kobayashi T, Aomatsu Y, Iwata H, Kin T, Kanehiro H, Hisanaga M, Ko S, Nagao M, Nakajima Y. Indefinite islet protection from autoimmune destruction in nonobese diabetic mice by agarose microencapsulation without immunosuppression. Transplantation 2003. 75:619-625.
52. Lee DY, Park SJ, Lee S, Nam JH, Byun Y. Highly poly(ethylene) glycolylated islets improve long-term islet allograft survival without immunosuppressive medication. Tissue Eng 2007. 13:2133-2141.
53. Dong H, Fahmy TM, Metcalfe SM, Morton SL, Dong X, Inverardi L, Adams DB, Gao W, Wang H. Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice. Plos One 2012. 7:e50265.
54. Soon-Shiong P, Feldman E, Nelson R, Heintz R, Yao Q, Yao Z, Zheng T, Merideth N, Skjak-Braek G, Espevik T, et al. Long-term reversal of diabetes by the injection of immunoprotected islets. Proc Natl Acad Sci USA 1993. 90:5843-5847.
55. Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T, Murphy M, Moloney MK, Schmehl M, Harris M, et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 1994. 343:950-951.
56. Elliot RB, Garkavenko O, Tan P, Skaletsky NN, Guliev A, Draznin B. Transplantation of microencapsulated neonatal porcine islets in patients with type 1 diabetes: safety and efficacy. 70th Scientific Sessions, American Diabetes Association. Orlando, Florida, USA, 2010.
57. Elliott RB, Escobar L, Tan PL, Muzina M, Zwain S, Buchanan C. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation 2007. 14:157-161.
58. Duvivier-Kali VF, Omer A, Lopez-Avalos MD, O'Neil JJ, Weir GC. Survival of microencapsulated adult pig islets in mice in spite of an antibody response. Am J Transplant 2004. 4:1991-2000.
59. Suzuki K, Bonner-Weir S, Trivedi N, Yoon KH, Hollister-Lock J, Colton CK, Weir GC. Function and survival of macroencapsulated syngeneic islets transplanted into streptozocin-diabetic mice. Transplantation 1998. 66:21-28.
60. Tze WJ, Cheung SC, Tai J, Ye H. Assessment of the in vivo function of pig islets encapsulated in uncoated alginate microspheres. Transplant Proc 1998. 30:477-478.
61. King A, Lau J, Nordin A, Sandler S, Andersson A. The effect of capsule composition in the reversal of hyperglycemia in diabetic mice transplanted with microencapsulated allogeneic islets. Diabetes Technol Ther 2003. 5:653-663.
62. Espevik T, Otterlei M, Skjak-Braek G, Ryan L, Wright SD, Sundan A. The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur J Immunol 1993. 23:255-261.
63. Otterlei M, Ostgaard K, Skjak-Braek G, Smidsrod O, Soon-Shiong P, Espevik T. Induction of cytokine production from human monocytes stimulated with alginate. J Immunother (1991) 1991. 10:286-291.
64. Lanza RP, Jackson R, Sullivan A, Ringeling J, McGrath C, Kuhtreiber W, Chick WL. Xenotransplantation of cells using biodegradable microcapsules. Transplantation 1999. 67:1105-1111.
65. Zimmermann U, Thurmer F, Jork A, Weber M, Mimietz S, Hillgartner M, Brunnenmeier F, Zimmermann H, Westphal I, Fuhr G, et al. A novel class of amitogenic alginate microcapsules for long-term immunoisolated transplantation. Ann N Y Acad Sci 2001. 944:199-215.
66. Sakai S, Ono T, Ijima H, Kawakami K. Modification of porous aminopropyl-silicate microcapsule membrane by electrically-bonded external anionic polymers. J Biomater Sci Polym Ed 2003. 14:643-652.
67. Zimmermann H, Zimmermann D, Reuss R, Feilen PJ, Manz B, Katsen A, Weber M, Ihmig FR, Ehrhart F, Gessner P, et al. Towards a medically approved technology for alginate-based microcapsules allowing longterm immunoisolated transplantation. J Mater Sci Mater Med 2005. 16:491-501.
68. Kulseng B, Thu B, Espevik T, Skjak-Braek G. Alginate polylysine microcapsules as immune barrier: permeability of cytokines and immunoglobulins over the capsule membrane. Cell Transplant 1997. 6:387-394.
69. Morch YA, Donati I, Strand BL, Skjak-Braek G. Effect of Ca2+, Ba2+, and Sr2+ on alginate microbeads. Biomacromolecules 2006. 7:1471-1480.
70. King A, Sandler S, Andersson A. The effect of host factors and capsule composition on the cellular overgrowth on implanted alginate capsules. J Biomed Mater Res 2001. 57:374-383.
71. Rokstad AM, Brekke OL, Steinkjer B, Ryan L, Kollarikova G, Strand BL, Skjak-Braek G, Lacik I, Espevik T, Mollnes TE. Alginate microbeads are complement compatible, in contrast to polycation containing microcapsules, as revealed in a human whole blood model. Acta Biomater 2011. 7:2566-2578.
72. Vandenbossche GM, Bracke ME, Cuvelier CA, Bortier HE, Mareel MM, Remon JP. Host reaction against alginate-polylysine microcapsules containing living cells. J Pharm Pharmacol 1993. 45:121-125.
73. Juste S, Lessard M, Henley N, Menard M, Halle JP. Effect of poly-L-lysine coating on macrophage activation by alginate-based microcapsules: assessment using a new in vitro method. J Biomed Mater Res A 2005. 72:389-398.
74. Pueyo ME, Darquy S, Capron F, Reach G. In vitro activation of human macrophages by alginate-polylysine microcapsules. J Biomater Sci Polym Ed 1993. 5:197-203.
75. Strand BL, Ryan TL, In't Veld P, Kulseng B, Rokstad AM, Skjak-Brek G, Espevik T. Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant 2001. 10:263-275.
76. Omer A, Duvivier-Kali V, Fernandes J, Tchipashvili V, Colton CK, Weir GC. Long-term normoglycemia in rats receiving transplants with encapsulated islets. Transplantation 2005. 79:52-58.
77. Kulseng B, Skjak-Braek G, Ryan L, Andersson A, King A, Faxvaag A, Espevik T. Transplantation of alginate microcapsules: generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. Transplantation 1999. 67:978-984.
78. De Vos P, De Haan BJ, Wolters GH, Strubbe JH, Van Schilfgaarde R. Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets. Diabetologia 1997. 40:262-270.
79. Jain K, Asina S, Yang H, Blount ED, Smith BH, Diehl CH, Rubin AL. Glucose control and long-term survival in biobreeding/Worcester rats after intraperitoneal implantation of hydrophilic macrobeads containing porcine islets without immunosuppression. Transplantation 1999. 68:1693-1700.
80. Iwata H, Takagi T, Amemiya H. Agarose microcapsule applied in islet xenografts (hamster to mouse). Transplant Proc 1992. 24: 52.
81. Yang KC, Qi Z, Wu CC, Shirouza Y, Lin FH, Yanai G, Sumi S. The cytoprotection of chitosan based hydrogels in xenogeneic islet transplantation: An in vivo study in streptozotocin-induced diabetic mouse. Biochem Biophys Res Commun 2010. 393:818-823.
82. Isayeva IS, Kasibhatla BT, Rosenthal KS, Kennedy JP. Characterization and performance of membranes designed for macroencapsulation/implantation of pancreatic islet cells. Biomaterials 2003. 24:3483-3491.
83. Jones KS, Sefton MV, Gorczynski RM. In vivo recognition by the host adaptive immune system of microencapsulated xenogeneic cells. Transplantation 2004. 78:1454-1462.
84. Lhommeau C, Toillon S, Pith T, Kessler L, Jesser C, Pinget M. Polyamide 4,6 membranes for the encapsulation of Langerhans islets: preparation, physico-chemical properties and biocompatibility studies. J Mater Sci Mater Med 1997. 8:163-174.
85. Qi Z, Yamamoto C, Imori N, Kinukawa A, Yang KC, Yanai G, Ikenoue E, Shen Y, Shirouzu Y, Hiura A, et al. Immunoisolation effect of polyvinyl alcohol (PVA) macroencapsulated islets in type 1 diabetes therapy. Cell Transplant 2012. 21:525-534.
86. Nadithe V, Mishra D, Bae YH. Poly(ethylene glycol) cross-linked hemoglobin with antioxidant enzymes protects pancreatic islets from hypoxic and free radical stress and extends islet functionality. Biotechnol Bioeng 2012. 109:2392-2401.
87. Aghajani-Lazarjani H, Vasheghani-Farahani E, Shojaosadati SA, Hashemi-Najafabadi S, Zahediasl S, Tiraihi T, Atyabi F. The effect of two different polyethylene glycol (PEG) derivatives on the immunological response of PEG grafted pancreatic islets. J Artif Organs 2010. 13:218-224.
88. Sefton MV. The good, the bad and the obvious: 1993 Clemson Award for Basic Research -Keynote Lecture. Biomaterials 1993. 14:1127-1134.
89. Klomp GF, Ronel SH, Hashiguchi H, D'Andrea M, Dobelle WH. Hydrogels for encapsulation of pancreatic islet cells. Trans Am Soc Artif Intern Organs 1979. 25:74-76.
90. Kessler L, Pinget M, Aprahamian M, Dejardin P, Damge C. In vitro and in vivo studies of the properties of an artificial membrane for pancreatic islet encapsulation. Horm Metab Res 1991. 23:312-317.
91. Maki T, Lodge JP, Carretta M, Ohzato H, Borland KM, Sullivan SJ, Staruk J, Muller TE, Solomon BA, Chick WL, et al. Treatment of severe diabetes mellitus for more than one year using a vascularized hybrid artificial pancreas. Transplantation 1993. 55:713-717.
92. Sun AM, Parisius W, Healy GM, Vacek I, Macmorine HG. The use, in diabetic rats and monkeys, of artificial capillary units containing cultured islets of Langerhans (artificial endocrine pancreas). Diabetes 1977. 26:1136-1139.
93. Lee SH, Hao E, Savinov AY, Geron I, Strongin AY, Itkin-Ansari P. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. Transplantation 2009. 87:983-991.
94. Sorenby AK, Kumagai-Braesch M, Sharma A, Hultenby KR, Wernerson AM, Tibell AB. Preimplantation of an immunoprotective device can lower the curative dose of islets to that of free islet transplantation: studies in a rodent model. Transplantation 2008. 86:364-366.
95. Geller RL, Loudovaris T, Neuenfeldt S, Johnson RC, Brauker JH. Use of an immunoisolation device for cell transplantation and tumor immunotherapy. Ann N Y Acad Sci 1997. 831:438-451.
96. Brauker J, Martinson LA, Young SK, Johnson RC. Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization. Transplantation 1996. 61:1671-1677.
97. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res 1995. 29:1517-1524.
98. Colton CK. Implantable biohybrid artificial organs. Cell Transplant 1995. 4:415-436.
99. Scharp DW, Swanson CJ, Olack BJ, Latta PP, Hegre OD, Doherty EJ, Gentile FT, Flavin KS, Ansara MF, Lacy PE. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes 1994. 43:1167-1170.
100. Scharp DW, Mason NS, Sparks RE. Islet immunoisolation: the use of hybrid artificial organs to prevent islet tissue rejection. World J Surg 1984. 8:221-229.
101. Hoesli CA, Luu M, Piret JM. A novel alginate hollow fiber bioreactor process for cellular therapy applications. Biotechnol Prog 2009. 25:1740-1751.
102. Silva AI, Mateus M. Development of a polysulfone hollow fiber vascular bio-artificial pancreas device for in vitro studies. J Biotechnol 2009. 139:236-249.
103. Dulong JL, Legallais C, Darquy S, Reach G. A novel model of solute transport in a hollow-fiber bioartificial pancreas based on a finite element method. Biotechnol Bioeng 2002. 78:576-582.
104. Zekorn T, Renardy M, Planck H, Zschocke P, Bretzel RG, Siebers U, Federlin K. Experiments on a new hollow fiber membrane for immuno isolated transplantation of islets of Langerhans. Horm Metab Res Suppl 1990. 25:202-206.
105. Altmah JJ. The bioartificial pancreas: macroencapsulation of insulin secreting cells in hollow fibers. J Diabet Complications 1988. 2:68-74.
106. Icard P, Penfornis F, Gotheil C, Boillot J, Cornec C, Barrat F, Altman JJ. Tissue reaction to implanted bioartificial pancreas in pigs. Transplant Proc 1990. 22:724-726.
107. Lanza RP, Borland KM, Staruk JE, Appel MC, Solomon BA, Chick WL. Transplantation of encapsulated canine islets into spontaneously diabetic BB/Wor rats without immunosuppression. Endocrinology 1992. 131:637-642.
108. Lanza RP, Borland KM, Lodge P, Carretta M, Sullivan SJ, Muller TE, Solomon BA, Maki T, Monaco AP, Chick WL. Treatment of severely diabetic pancreatectomized dogs using a diffusion-based hybrid pancreas. Diabetes 1992. 41:886-889.
109. Lanza RP, Butler DH, Borland KM, Harvey JM, Faustman DL, Solomon BA, Muller TE, Rupp RG, Maki T, Monaco AP, et al. Successful xenotransplantation of a diffusion-based biohybrid artificial pancreas: a study using canine, bovine, and porcine islets. Transplant Proc 1992. 24:669-671.
110. Lacy PE, Hegre OD, Gerasimidi-Vazeou A, Gentile FT, Dionne KE. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 1991. 254:1782-1784.
111. Prevost P, Flori S, Collier C, Muscat E, Rolland E. Application of AN69 hydrogel to islet encapsulation: evaluation in the streptozotocin-induced diabetic rat model. Transplant Proc 1995. 27:3393-3395.
112. Rivereau AS, Darquy S, Chaillous L, Maugendre S, Gouin E, Reach G, Sai P. Reversal of diabetes in nonobese diabetic mice by xenografts of porcine islets entrapped in hollow fibres composed of polyacrylonitrile-sodium methallylsulphonate copolymer. Diabetes Metab 1997. 23:205-212.
113. Schrezenmeir J, Gero L, Laue C, Kirchgessner J, Muller A, Huls A, Passmann R, Hahn HJ, Kunz L, Mueller-Klieser W, et al. The role of oxygen supply in islet transplantation. Transplant Proc 1992. 24:2925-2929.
114. Cornolti R, Figliuzzi M, Remuzzi A. Effect of microand macroencapsulation on oxygen consumption by pancreatic islets. Cell Transplant 2009. 18:195-201.
115. Storrs R, Dorian R, King SR, Lakey J, Rilo H. Preclinical development of the Islet Sheet. Ann N Y Acad Sci 2001. 944:252-266.
116. Chick WL, Perna JJ, Lauris V, Low D, Galletti PM, Panol G, Whittemore AD, Like AA, Colton CK, Lysaght MJ. Artificial pancreas using living beta cells:. effects on glucose homeostasis in diabetic rats. Science 1977. 197:780-782.
117. Whittemore AD, Chick WL, Galletti PM, Mannick JA. Function of hybrid artificial pancreas in diabetic rats. Surg Forum 1977. 28:93-97.
118. Tatarkiewicz K, Sitarek E, Sabat M, Orlowski T. Long-term culture of non-purified rat islets embedded in hydrogel matrix. Transplant Proc 1996. 28:831-832.
119. Ohgawara H, Miyazaki J, Karibe S, Katagiri N, Tashiro F, Akaike T. Assessment of pore size of a semipermeable membrane for immunoisolation on xenoimplantation of pancreatic B cells using a diffusion chamber. Transplant Proc 1995. 27:3319-3320.
120. Kessler L, Aprahamian M, Keipes M, Damge C, Pinget M, Poinsot D. Diffusion properties of an artificial membrane used for Langerhans islets encapsulation: an in vitro test. Biomaterials 1992. 13:44-49.
121. Whittemore AD, Chick WL, Galletti PM, Like AA, Colton CK, Lysaght MJ, Richardson PD. Effects of the hybrid artificial pancreas in diabetic rats. Trans Am Soc Artif Intern Organs 1977. 23:336-341.
122. De Vos P, Hillebrands JL, De Haan BJ, Strubbe JH, Van Schilfgaarde R. Efficacy of a prevascularized expanded polytetrafluoroethylene solid support system as a transplantation site for pancreatic islets. Transplantation 1997. 63:824-830.
123. Juang JH, Bonner-Weir S, Ogawa Y, Vacanti JP, Weir GC. Outcome of subcutaneous islet transplantation improved by polymer device. Transplantation 1996. 61:1557-1561.
124. Pileggi A, Molano RD, Ricordi C, Zahr E, Collins J, Valdes R, Inverardi L. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation 2006. 81:1318-1324.
125. Valdes R, Martin S, Cravioto A, Tenopala J. Biological encapsulation as a new model for preservation of islets of Langerhans. Transplant Proc 1998. 30:481.
126. Colton CK, Avgoustiniatos ES. Bioengineering in development of the hybrid artificial pancreas. J Biomech Eng 1991. 113:152-170.
127. Hirotani S, Ohgawara H, Agishi T, Akaike T, Miyazaki S. A bio-artificial endocrine pancreas for the treatment of diabetes. Transplant Proc 1998. 30:485-489.
128. Andersson A, Eizirik DL, Hellerstrom C, Johnson RC, Pipeleers DG. Morphology of encapsulated human pancreatic islets transplanted into nude mice. Transplant Proc 1994. 26:802-803.
129. Rafael E, Wernerson A, Arner P, Wu GS, Tibell A. In vivo evaluation of glucose permeability of an immunoisolation device intended for islet transplantation: a novel application of the microdialysis technique. Cell Transplant 1999. 8:317-326.
130. Rafael E, Wu GS, Hultenby K, Tibell A, Wernerson A. Improved survival of macroencapsulated islets of Langerhans by preimplantation of the immunoisolating device: a morphometric study. Cell Transplant 2003. 12:407-412.
131. Yakhnenko I, Wong WK, Katkov, II, Itkin-Ansari P. Cryopreservation of human insulin expressing cells macroencapsulated in a durable therapeutic immunoisolating device theracyte. Cryo Letters 2012. 33:518-531.
132. Kumagai-Braesch M, Jacobson S, Mori H, Jia X, Takahashi T, Wernerson A, Flodstrom-Tullberg M, Tibell A. The TheraCyt device protects against islet allograft rejection in immunized hosts. Cell Transplant 2013. 22:1137-1146.
133. Borg DJ, Bonifacio E. The use of biomaterials in islet transplantation. Curr Diab Rep 2011. 11:434-444.
134. Krishnamurthy NV, Gimi B. Encapsulated cell grafts to treat cellular deficiencies and dysfunction. Crit Rev Biomed Eng 2011. 39:473-491.
135. Khanna O, Larson JC, Moya ML, Opara EC, Brey EM. Generation of alginate microspheres for biomedical applications. J Vis Exp 2012. 66:pii3388.
136. Zimmermann H, Shirley SG, Zimmermann U. Alginate-based encapsulation of cells: past, present, and future. Curr Diab Rep 2007. 7:314-320.
137. Fiszman GL, Karara AL, Finocchiaro LM, Glikin GC. A laboratory scale device for microencapsulation of genetically engineered cells into alginate beads. Electron J Biotechnol 2002. 5:23-24.
138. Sun AM. Microencapsulation of pancreatic islet cells: a bioartificial endocrine pancreas. Methods Enzymol 1988. 137:575-580.
139. Duvivier-Kali VF, Omer A, Parent RJ, O'Neil JJ, Weir GC. Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane. Diabetes 2001. 50:1698-1705.
140. Nguyen MK, Lee DS. Injectable biodegradable hydrogels. Macromol Biosci 2010. 10:563-579.
141. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev 2001. 101:1869-1879.
142. Nicodemus GD, Bryant SJ. Cell encapsulation in biodegradable hydrogels for tissue engineering applications. Tissue Eng Part B Rev 2008. 14:149-165.
143. De Vos P, Van Straaten JF, Nieuwenhuizen AG, de Groot M, Ploeg RJ, De Haan BJ, Van Schilfgaarde R. Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth? Diabetes 1999. 48:1381-1388.
144. Xin ZL, Ge SL, Wu XK, Jia YJ, Hu HT. Intracerebral xenotransplantation of semipermeable membraneencapsuled pancreatic islets. World J Gastroenterol 2005. 11:5714-5717.
145. Wilson JT, Chaikof EL. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev 2008. 60:124-145.
146. Lee DY, Yang K, Lee S, Chae SY, Kim KW, Lee MK, Han DJ, Byun Y. Optimization of monomethoxypolyethylene glycol grafting on the pancreatic islet capsules. J Biomed Mater Res 2002. 62:372-377.
147. Jang JY, Lee DY, Park SJ, Byun Y. Immune reactions of lymphocytes and macrophages against PEG-grafted pancreatic islets. Biomaterials 2004. 25:3663-3669.
148. Krol S, del Guerra S, Grupillo M, Diaspro A, Gliozzi A, Marchetti P. Multilayer nanoencapsulation. New approach for immune protection of human pancreatic islets. Nano Lett 2006. 6:1933-1939.
149. Teramura Y, Kaneda Y, Iwata H. Islet-encapsulation in ultra-thin layer-by-layer membranes of poly(vinyl alcohol) anchored to poly(ethylene glycol)-lipids in the cell membrane. Biomaterials 2007. 28:4818-4825.
150. Khanna O, Moya ML, Opara EC, Brey EM. Synthesis of multilayered alginate microcapsules for the sustained release of fibroblast growth factor-1. J Biomed Mater Res A 2010. 95:632-640.
151. Teramura Y, Iwata H. Improvement of graft survival by surface modification with poly(ethylene glycol)-lipid and urokinase in intraportal islet transplantation. Transplantation 2011. 91:271-278.
152. Baruch L, Benny O, Gilert A, Ukobnik M, Ben Itzhak O, Machluf M. Alginate-PLL cell encapsulation system Co-entrapping PLGA-microspheres for the continuous release of anti-inflammatory drugs. Biomed Microdevices 2009. 11:1103-1113.
153. Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Sama D, Calatroni A. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. J Cell Biochem 2009.106:83-92.
154. Leung A, Lawrie G, Nielsen LK, Trau M. Synthesis and characterization of alginate/poly-L-ornithine/alginate microcapsules for local immunosuppression. J Microencapsul 2008. 25:387-398.
155. Senzolo M, Coppell J, Cholongitas E, Riddell A, Triantos CK, Perry D, Burroughs AK. The effects of glycosaminoglycans on coagulation: a thromboelastographic study. Blood Coagul Fibrinolysis 2007. 18:227-236.
156. Bunger CM, Tiefenbach B, Jahnke A, Gerlach C, Freier T, Schmitz KP, Hopt UT, Schareck W, Klar E, de Vos P. Deletion of the tissue response against alginate-pll capsules by temporary release of co-encapsulated steroids. Biomaterials 2005. 26:2353-2360.
157. Pedraza E, Coronel MM, Fraker CA, Ricordi C, Stabler CL. Preventing hypoxia-induced cell death in beta cells and islets via hydrolytically activated, oxygengenerating biomaterials. Proc Natl Acad Sci U S A 2012. 109:4245-4250.
158. Mansouri S, Merhi Y, Winnik FM, Tabrizian M. Investigation of layer-by-layer assembly of polyelectrolytes on fully functional human red blood cells in suspension for attenuated immune response. Biomacromolecules 2011. 12:585-592.
159. Pickup JC, Zhi ZL, Khan F, Saxl T, Birch DJ. Nanomedicine and its potential in diabetes research and practice. Diabetes Metab Res Rev 2008. 24:604-610.
160. Wilson JT, Cui W, Chaikof EL. Layer-by-layer assembly of a conformal nanothin PEG coating for intraportal islet transplantation. Nano Lett 2008. 8:1940-1948.
161. Luan NM, Teramura Y, Iwata H. Layer-by-layer coimmobilization of soluble complement receptor 1 and heparin on islets. Biomaterials 2011. 32:6487-6492.
162. Tatsumi K, Ohashi K, Teramura Y, Utoh R, Kanegae K, Watanabe N, Mukobata S, Nakayama M, Iwata H, Okano T. The non-invasive cell surface modification of hepatocytes with PEG-lipid derivatives. Biomaterials 2012. 33:821-828.
163. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008. 26:443-452.
164. Matveyenko AV, Georgia S, Bhushan A, Butler PC. Inconsistent formation and nonfunction of insulin-positive cells from pancreatic endoderm derived from human embryonic stem cells in athymic nude rats. Am J Physiol Endocrinol Metab 2010. 299:E713-E720.
165. Candiello J, Singh SS, Task K, Kumta PN, Banerjee I. Early differentiation patterning of mouse embryonic stem cells in response to variations in alginate substrate stiffness. J Biol Eng 2013. 7:9.
166. Kadam S, Muthyala S, Nair P, Bhonde R. Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes. Rev Diabet Stud 2010. 7:168-182.
167. Ngoc PK, Phuc PV, Nhung TH, Thuy DT, Nguyet NT. Improving the efficacy of type 1 diabetes therapy by transplantation of immunoisolated insulin-producing cells. Hum Cell 2011. 24:86-95.
168. Davis NE, Beenken-Rothkopf LN, Mirsoian A, Kojic N, Kaplan DL, Barron AE, Fontaine MJ. Enhanced function of pancreatic islets co-encapsulated with ECM proteins and mesenchymal stromal cells in a silk hydrogel. Biomaterials 2012. 33:6691-6697.
169. Chandra V, Swetha G, Muthyala S, Jaiswal AK, Bellare JR, Nair PD, Bhonde RR. Islet-like cell aggregates generated from human adipose tissue derived stem cells ameliorate experimental diabetes in mice. Plos One 2011. 6:e20615.
170. Mason MN, Mahoney MJ. Selective beta-cell differentiation of dissociated embryonic pancreatic precursor cells cultured in synthetic polyethylene glycol hydrogels. Tissue Eng Part A 2009. 15:1343-1352.
171. Zhu FF, Zhang PB, Zhang DH, Sui X, Yin M, Xiang TT, Shi Y, Ding MX, Deng H. Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells. Diabetologia 2011. 54:2325-2336.
172. Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, Goland R, Leibel RL, Melton DA. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A 2009. 106:15768-15773.
173. Tateishi K, He J, Taranova O, Liang G, D'Alessio AC, Zhang Y. Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem 2008. 283:31601-31607.
174. Lysy PA, Weir GC, Bonner-Weir S. Concise review: pancreas regeneration: recent advances and perspectives. Stem Cells Transl Med 2012. 1:150-159.
175. Blyszczuk P, Czyz J, Kania G, Wagner M, Roll U, St-Onge L, Wobus AM. Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proc Natl Acad Sci U S A 2003. 100:998-1003.
176. Korsgren O, Nilsson B. Improving islet transplantation: a road map for a widespread application for the cure of persons with type I diabetes. Curr Opin Organ Transplant 2009. 14:683-687.
177. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2011. 8(1):6-16.
178. Shapiro JA. Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome. Rev Diabet Stud 2012. 9(4):385-406.
179. Vaithilingam V, Oberholzer J, Guillemin GJ, Tuch BE. The humanized NOD/SCID mouse as a preclinical model to study the fate of encapsulated human islets. Rev Diabet Stud 2010. 7(1):62-73.
180. Vaithilingam V, Tuch BE. Islet transplantation and encapsulation: an update on recent developments. Rev Diabet Stud 2011. 8(1):51-67.
181. Parkinson J. Developing a comprehensive system to protect islet cells and deliver transplants to all with insulin dependence. http://www.diabetescare.net/content_upclose_detail.asp?id =446538.2012. Accessed July 30, 2013.
182. Hanuman Medical Foundation. An Example of Academic Research Presented as A Path to the Cure. http://www.hanumanmedicalfoundation.org/blog/2009/11/09/an-example-of-academic-research-presented-as-a-pathto-the-cure/.2009. Accessed July 30, 2013.
183. Mao GH, Chen GA, Bai HY, Song TR, Wang YX. The reversal of hyperglycaemia in diabetic mice using PLGA scaffolds seeded with islet-like cells derived from human embryonic stem cells. Biomaterials 2009. 30:1706-1714.